A 2019 paper [238] reported the identification of a multi-HLA-class I–binding (promiscuous) HSP70-derived epitope peptide that binds to HLA-A*0201, *0206, and *2402 and may be applicable to cancer immunotherapy in patients with HLA-A*2402+, *0201+, and *0206+ HSP70-expressing tumors. Here, HLA-A is linked to cancer.